Biogen
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.
BIIB Key Statistics
Stock Snapshot
With a market cap of 37.6B, Biogen(BIIB) trades at $254.37. The stock has a price-to-earnings ratio of 108.93.
As of 2026-11-05, Biogen(BIIB) stock has fluctuated between $252.00 and $255.70. The current price stands at $254.37, placing the stock +0.9% above today's low and -0.5% off the high.
The Biogen(BIIB)'s current trading volume is 56.14K, compared to an average daily volume of 1.43M.
In the last year, Biogen(BIIB) shares hit a 52-week high of $258.78 and a 52-week low of $148.51.
In the last year, Biogen(BIIB) shares hit a 52-week high of $258.78 and a 52-week low of $148.51.
BIIB News
Biogen reported third quarter 2026 revenue of US$2,804.1 million and a net loss of US$20.6 million, and then shared expanded Alzheimer’s data on diranersen and...
Biogen (BIIB) is back in focus after fresh Alzheimer’s data and mixed third quarter figures, as investors weigh revenue growth, continued Leqembi uptake, and th...
Analyst ratings
70%
of 37 ratingsPeople also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.